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ABSTRACT
A simple, rapid and sensitive kinetic spectrophotometric method is described for the analysis of naftidrofuryl oxalate (NF) and
vincamine (VN) in pure form and in their pharmaceutical preparations. The procedure was based on the kinetic investigation of the
oxidation of the studied drugs with alkaline potassium permanganate and the absorbance of the produced manganate species was
measured at 610 nm. Variables affecting the color development were investigated and the conditions were optimized. The concentration of the studied drugs was calculated using the regression equations for the fixed-time method. The determination of the two
drugs by fixed absorbance and rate constant methods was possible but the fixed time method was more applicable. The reliability
and analytical performance of the proposed method including linearity, ranges, precision, accuracy, detection and quantification
limits were statistically validated. Calibration graphs are linear over the concentration ranges of 3-15 µg/mL and 4-14 µg/mL for NF
and VN, respectively. The proposed method was satisfactorily applied for analysis of pharmaceutical preparations containing the
studied drugs. A proposal of the reaction pathway was postulated.
Key words: naftidrofuryl oxalate, vincamine, potassium permanganate, kinetic spectrophotometry, pharmaceutical preparations

INTRODUCTION
Naftidrofuryl oxalate (NF), 2-(diethylamino)ethyl
2-[(naphthalen-1-yl)methyl]-3-(tetrahydrofuran-2-yl)
propanoate hydrogen oxalate, is a vasodilator drug used
in the treatment of peripheral and cerebral vascular
disorders. It is claimed to enhance the cellular oxidative
capacity thereby protecting cells against ischemia (1). NF
is an official drug in the British Pharmacopoeia (2) where
a nonaqueous potentiometric titration and HPLC procedures were described for the assay of NF bulk powder
and capsules, respectively. Few analytical methods have
been reported for the determination of NF in biological
fluids and/or pharmaceutical preparations. Most of these
studies focused on HPLC-UV detection(3,4), HPLC-fluorescence detection(5-8) and phosphorimetric analysis (9-12).
Others included potentiometric method using NF ionselective electrodes (13), flow injection analysis with
* Author for correspondence. Tel: +20-3-4871317;
Fax: +20-3-4871351; E-mail: tbelaleg@yahoo.com

fluorescence optosensor (14) and spectrophotometry(15).
Vincamine (VN), methyl (3α, 16α)-14, 15-dihydro14ß-hydroxy eburnamenine-14-carboxylate, is an alkaloid obtained from Vinca minor (Apocyanaceae). It is
claimed to increase cerebral circulation and utilization
of oxygen and has been used in a variety of cerebral
disorders(1). Several methods have been reported for the
determination of VN in different matrices. VN has been
determined in biological fluids by HPLC(16-19) and GC(2023)
methods. A fluorimetric method was described for
the estimation of VN in biological fluids obtained from
rats(24). In pharmaceutical preparations, VN has been
determined by derivative and chemometric spectrophotometry(25-28), HPLC(19,25,27-29), TLC(28) and PMR(30)
procedures. Gravimetric, titrimetric and spectrometric
analyses of VN were carried out based on its complexation with thiocyanate ion(31,32). VN has been also determined in plant tissue cultures of Vinca minor by TLC(33)
and HPLC(34) methods.
Analytical
procedures
based
on
kinetic
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spectrophotometry are still lacking in the literature for
the determination of NF or VN in pharmaceutical formulations. Kinetic methods are considered of great interest
in chemical and pharmaceutical analysis (35). Potassium
permanganate in alkaline medium easily reacts with
compounds susceptible to oxidation with the formation of
manganate species which can be followed up spectrophotometrically. Several pharmaceutical compounds were
determined through this approach(36-40). In this work, a
kinetics-based spectrophotometric method was developed for the assay of NF and VN. The method is based
on oxidizing the two drugs with alkaline KMnO 4 at
room temperature, and subsequently the rate of appearance of the green colored product was monitored at
610 nm. The proposed method is simple, rapid, costeffective and readily adaptable to both bulk powders and
dosage forms, hence more suitable for the application in
quality control laboratories in developing countries.

MATERIALS AND METHODS

USA) with matched 1-cm quartz cells.
II. Drugs and Chemicals
All chemicals and solvents used were of analytical
reagent grade. Naftidrofuryl oxalate was kindly donated
by Minapharm Pharmaceuticals and Chemical Industries, Cairo, Egypt. Vincamine was kindly provided by
GlaxoSmithKline S.A.E., El-Salam city, Cairo, Egypt.
Pharmaceutical preparations examined in this study were
purchased from the local market and they included Praxilene ® tablets (Minapharm Pharmaceuticals and Chemical Industries, Cairo, Egypt, under license of Merck
Serono, BN. 5AE0028) labeled to contain 200 mg NF
per tablet, Oxybral® capsules (GlaxoSmithKline S.A.E.,
El-Salam city, Cairo, Egypt, BN. 071058A) labeled to
contain 30 mg VN per capsule and Oxybral® ampoules
(GlaxoSmithKline S.A.E., El-Salam city, Cairo, Egypt,
BN. 074983A) labeled to contain 15 mg VN per 2 mL.
III. General Procedure

I. Apparatus
Spectrophotometric measurements were performed
on a Perkin-Elmer Lambda EZ201 UV-visible spectrophotometer (PerkinElmer, Waltham, Massachusetts,

Potassium permanganate solution, 12 mg/mL (0.076
M), and sodium hydroxide solution, 0.5 M, were prepared
in distilled water. NF standard solution, 3 mg/mL
(6.33 × 10 -3 M), and VN standard solution, 0.5 mg/mL
(1.41 × 10 -3 M), were prepared in acetonitrile. Working

Table 1. Experimental and analytical parameters for the kinetic determination of NF and VN
Parameter
Temperature (°C)
Time (min)
Concentration range [M]
Molar absorptivity (ε)
(L mole-1 cm-1)
Regression equation
A=a+b×C
Correlation coefficient ( r )

25 ± 2

25 ± 2

35

20

6.33 × 10-6 - 3.17 × 10-5

1.13 × 10-5 - 3.95 × 10-5

25795

20593

A = 0.0395 + 25794.84 C

A = -0.0099 + 20592.51 C

0.9974

0.9986

Sa

0.0067

0.0054

Sbb

388.65

200.24

1.51

0.97

Sy/x

d

0.0055
e

0.0047

LOD [M]

8.01 × 10

-7

1.19 × 10-6

LOQf [M]

2.67 × 10-6

3.97 × 10-6

: Standard deviation of the intercept.
: Standard deviation of the slope.
c
: Percentage relative standard deviation of the slope
d
: Standard deviation of residuals.
e
: Limit of detection.
f
: Limit of quantification.
b

VN

a

Sb%c

a

NF
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IV. Assay of Pharmaceutical Preparations
(I) For NF Tablets
A total of 20 tablets (“Praxilene ®” tablets) were
weighed and finely powdered. To an accurately weighed
quantity of the powder containing the equivalent of
30 mg of NF, 60 mL of acetonitrile were added, stirred
for 10 min and then filtered into a 100 mL volumetric
flask. The residue was washed with two 10 mL portions
of acetonitrile, washings were added to the filtrate and
diluted to the volume with acetonitrile and aliquots were
treated as described in General Procedure.
(II) For VN Capsules
To an accurately weighed quantity of the powdered
content of Oxybral® capsules equivalent to 10 mg of VN,
60 mL of acetonitrile were added and stirred for 10 min
and then filtered into a 100 mL volumetric flask. The
residue was washed with two 10 mL portions of acetonitrile, washings were added to the filtrate and diluted
to volume with acetonitrile and aliquots were treated as
described in General Procedure.

RESULTS AND DISCUSSION
NF and VN react with alkaline potassium permanganate to give the green colored manganate species that
absorbs maximally at 610 nm (Figure 1). The extent
of formation of this species depends on the concentration of reactants, alkalinity of solution and temperature.
Therefore, various experimental parameters affecting
the development and the stability of the reaction product
were optimized by changing each variable in turn while
keeping all others constant.
I. Kinetics and Optimization of the Reaction Conditions
The effect of potassium permanganate concentration on the reaction was studied over the range of 3.04
× 10 -3 to 9.12 × 10 -3 M for NF and 3.8 × 10 -3 to 1.52 ×
10 -2 M for VN. The maximum absorbance was obtained
at the concentration 7.6 × 10 -3 M (1 mL of 0.076 M
KMnO 4 diluted to final reaction volume 10 mL) for both
NF and VN. Higher concentrations of potassium permanganate yielded lower absorbance values, probably due
to decomposition of the product (Figure 2). Complete
reaction between the investigated drugs and potassium

1
0.8

Absorbance

solutions, 300 µg/mL NF (6.33 × 10 -4 M) and 100 µg/mL
VN (2.82 × 10 -4 M), were prepared by dilution of standard solutions with acetonitrile. These solutions were
found stable for at least 4 days and were stored refrigerated at 4°C during this study.
Accurate volumes of NF or VN working solutions
with the concentration ranges shown in Table 1 were
transferred into 10-mL volumetric flasks containing the
appropriate volumes of potassium permanganate solution (1 mL) and sodium hydroxide solution (3 mL). The
solutions were diluted to the volume with distilled water,
mixed well and left at room temperature (25 ± 2°C) for
a fixed time of 35 min for NF and 20 min for VN. The
absorbance of solutions was measured at 610 nm against
similarly treated blanks. The drug concentrations were
then computed from the corresponding regression equations of the calibration graphs for the fixed time method.

0.4
0.2
0
560

580

600

620

640

660

680

700

Wavelength (nm)

Figure 1. Absorption spectra of the reaction product of (a) 2.53 × 10 -5
M NF and (b) 2.82 × 10 -5 M VN.

0.8

(III) For VN Ampoules

a
0.7

A610

An accurate volume of the mixed contents of
five Oxybral® ampoules equivalent to 10 mg of VN
was transferred into a separating funnel and alkalinized with 10 mL of 0.5 M NaOH. VN was extracted by
shaking the aqueous layer with 3 portions of chloroform
(10 mL each). The organic layer was then collected and
evaporated to dryness under vacuum. The residue was
dissolved in acetonitrile by sonication for 10 min. It was
then transferred quantitatively into a 100 mL volumetric
flask, diluted to the volume with acetonitrile and aliquots
were treated as described in General Procedure.

0.6

0.6
0.5

b

0.4
0.3
0.25

0.5

0.75

1

1.25

1.5

1.75

2

Volume of 0.076 M KMnO4 (mL)

Figure 2. Effect of KMnO4 concentration on the reaction product of
(a) 2.11 × 10 -5 M NF and (b) 3.39 × 10 -5 M VN using optimum conditions for each compound.
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Regression of log (rate) versus log [C] gave the
following regression equations:
log (rate) = 0.872603 + 0.89630 log [NF], r = 0.998338
log (rate) = 1.382608 + 1.03817 log [VN], r = 0.998847

0.8
b
0.7

a

A610

permanganate took place only in alkaline medium. The
influence of alkalinity was investigated in the range
of 0.025 to 0.175 M NaOH for NF and 0.025 to 0.2 M
NaOH for VN. The maximum absorbance values were
obtained at concentration 0.15 M (3 mL 0.5 M NaOH)
for both drugs (Figure 3). The effect of temperature
was studied in the range of 25-60°C. The rate of reaction increased with increasing temperature; however,
25 ± 2°C was selected as the optimum temperature due
to low reproducibility of absorbance values at higher
temperature. In order to ascertain the stoichiometry of
the studied reactions, Job’s method of continuous variation(41) was applied. For both drugs, Job’s method plot
(Figure 4) reached a maximum value at a mole fraction
of 0.3 for NF and 0.2 for VN which indicated a reaction
ratio of 1: 2 and 1: 4 (drug : KMnO 4) for NF and VN,
respectively. The reaction pathway can be explained by
the oxidation of the tertiary amine groups into N-oxide.
It has been reported that compounds possessing tertiary
amine groups are liable to oxidation by alkaline potassium permanganate (39,40). The following schemes represent the proposed pathways for the reaction between the
investigated drugs and KMnO 4 in alkaline medium.

0.6

0.5
0.5

1

1.5

2

2.5

3

3.5

4

Volume of 0.5 M NaOH (mL)

Figure 3. Effect of NaOH concentration on the reaction product of (a)
2.11 × 10 -5 M NF and (b) 3.39 × 10 -5 M VN using optimum conditions
for each compound.
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The rate of reaction was found to be drug dependant. The rates were followed at room temperature with
various concentrations of the investigated drugs in the
range of 6.33 × 10 -6 to 3.17 × 10 -5 M (3-15 µg/mL) for
NF and 1.13 × 10 -5 to 3.95 × 10 -5 M (4-14 µg/mL) for VN,
keeping KMnO 4 and NaOH constant at high concentrations as above. The graphs shown in Figures 5 and
6, clearly demonstrated that the reaction rates obey the
following equation:
Rate = K` × [C]n . .................................................. (1)
Where K` is the pseudo-order rate constant and n is
the order of reaction. The rate of reactions could be estimated as ΔA/Δt, where A is the absorbance and t is the
time in seconds. Taking logarithms of rates and concentrations (Table 2), equation (1) is transformed into:
log (rate) = log (ΔA/Δt) = log K`+ n log [C]............ (2)

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

Vd /(Vd+Vr)

Figure 4. Continuous variation plot for (a) NF and (b) VN. Concentration of solutions of both drugs and the reagent (KMnO4) was 1 ×
10 -2 M.

Table 2. Values of logarithms of rates and concentrations for NF
and VN with alkaline KMnO4 using optimum conditions for each
compound
Compound

NF

VN

log C[M]

log ΔA/Δt

-5.198

-3.799

-4.896

-3.500

-4.720

-3.343

-4.597

-3.259

-4.499

-3.167

-4.974

-3.741

-4.772

-3.582

-4.646

-3.448

-4.549

-3.348

-4.469

-3.255

-4.403

-3.177
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The determination of NF and VN under the optimized experimental conditions mentioned above,
in which the potassium permanganate and sodium
hydroxide concentrations were several hundreds times
that of either drug, would result in pseudo-zero conditions with respect to their concentrations and the rate of
reaction will be directly proportional to the concentration of NF or VN in a pseudo-first-order rate equation as
follows:
Rate = K` × [C]…………………………….. (3)
where K` is the pseudo-first-order rate constant.
Equation (3) was the basis for several experiments,
which were run to obtain concentrations of the investigated drugs using the rate data. Rate constant, fixedconcentration and fixed-time methods (42) were tested and
the most suitable analytical method was selected taking
into account the applicability, sensitivity (i,e. the slope
of the calibration graph), correlation coefficient (r) and
intercept (a).
(I) Rate-constant Method
Graphs of log (absorbance) versus time for NF
concentrations in the range of 6.33 × 10 -6 - 3.17 × 10 -5
M (3-15 µg/mL) and VN concentrations in the range of
2.26 × 10 -5 - 3.95 × 10 -5 M (8 - 14 µg/mL) were plotted
and all appeared to be rectilinear. Pseudo-first-order rate
constants (K`) corresponding to different concentrations of the investigated drugs [C] were calculated from
the slopes multiplied by -2.303. Regression of K` values
versus [C] gave the equations:
K` = 0.00205 + 18.89 [NF], r = 0.98364
K` = -0.00186 + 28.74 [VN], r = 0.49247
The method suffered from poor linearity especially for VN as indicated from its r value, therefore this
method was excluded.
(II) Fixed-concentration Method
Reaction rates were determined for different
concentrations of the investigated drugs. A pre-selected
absorbance value was fixed (0.4 for both NF and VN)
for different concentrations of the studied drugs, in the
range of 1.27 × 10 -5 - 3.17 × 10 -5 M (6-15 µg/mL) for NF
and 2.26 × 10 -5 - 3.95 × 10 -5 M (8-14 µg/mL) for VN and
the time required for each concentration to reach the preselected absorbance value was measured in seconds. The
reciprocal of time (1/t) versus drug concentrations was
plotted and the following equations were obtained by

(III) Fixed-time Method
Reaction rates were determined for different
concentrations of the investigated drugs. At a preselected fixed time, which was accurately determined,
the absorbance was measured. Calibration graphs of
the absorbance (A) versus initial concentration [C] were
established at different fixed-time intervals of 2-40
min for NF and 1-40 min for VN (Figures 5 and 6) with
the regression equations assembled in Table 3. It was
found that the slopes increase with time and the most
acceptable values for the intercept and the correlation
coefficient(r) were obtained at a fixed-time of 35 min
for NF and 20 min for VN therefore they were chosen as

1

Absorbance at 610 nm

II. Appraisal of Kinetic Methods

linear regression:
1/t = -1.5 × 10 -2 + 164.25 [NF], r = 0.98747
1/t = -2.6 × 10 -2 + 1113.62 [VN], r = 0.96103
The concentration ranges giving the most satisfactory calibration graphs were limited (6-15 µg/mL for NF
and 8-14 µg/mL for VN) with poor linearity and therefore the method is excluded.

5
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Figure 5. Absorbance versus time graphs for the reaction of NF and
alkaline potassium permanganate. Concentrations of NF: (1) 6.33 ×
10 -6, (2) 1.27 × 10 -5, (3) 1.90 × 10 -5, (4) 2.53 × 10 -5, (5) 3.17 × 10 -5 M.

6
0.8

Absorbance at 610 nm

Hence, K`= 7.46 sec -1 for NF and 24.13 sec -1 for VN
and the reaction is pseudo-first order (n = 1) with respect
to NF and VN.
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Figure 6. Absorbance versus time graphs for the reaction of VN and
alkaline potassium permanganate. Concentrations of VN: (1) 1.13 ×
10 -5, (2) 1.69 × 10 -5, (3) 2.26 × 10 -5, (4) 2.82 × 10 -5, (5) 3.39 × 10 -5, (6)
3.95 × 10 -5 M.
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Table 3. Regression equations at different fixed-times for NF in the
range 6.33 × 10 -6 - 3.17 × 10 -5 M and VN in the range 1.13 × 10 -5 3.95 × 10 -5 M with alkaline KMnO4 using optimum conditions for
each compound
Compound

Time

Regression equation

(r)

NF

2
4
6
8
10
12
14
16
20
25
30
35
40

A = -0.01943 + 9504.05 C
A = -0.01354 + 12803.07 C
A = -0.01976 + 15992.96 C
A = -0.01196 + 17508.15 C
A = 0.01194 + 18218.71 C
A = 0.00022 + 21297.50 C
A = 0.01161 + 22403.06 C
A = 0.02745 + 23348.12 C
A = 0.03274 + 24994.74 C
A = 0.10503 + 25716.40 C
A = 0.13035 + 25605.02 C
A = 0.03954 + 25794.84 C
A = 0.14524 + 25842.15 C

0.99929
0.99971
0.99971
0.99974
0.99832
0.99998
0.99909
0.99825
0.99844
0.99769
0.99757
0.99741
0.99734

A = 0.00637 + 11816.06 C
A = 0.00849 + 12979.56 C
A = 0.00180 + 14482.97 C
A = 0.01430 + 15080.14 C
A = 0.00015 + 16569.02 C
A = -0.00258 + 17490.14 C
A = -0.01482 + 18700.25 C
A = -0.02486 + 19666.37 C
A = -0.00989 + 20592.51 C
A = -0.01616 + 20511.65 C
A = -0.00879 + 20608.64 C
A = -0.00575 + 20744.71 C
A = -0.00440 + 20658.66 C

0.99781
0.99910
0.99959
0.99693
0.99861
0.99884
0.99883
0.99759
0.99857
0.99660
0.99677
0.99655
0.99561

VN

1
2
4
6
8
10
12
14
20
25
30
35
40

Table 4. Precision and accuracy for the proposed fixed time kinetic
method for the determination of NF and VN
Compound

NF

VN

Nominal Value
(µg/mL)

% Recovery*

RSD (%)

3

100.33

1.16

6

100.67

1.39

12

100.08

0.41

4

101.25

1.80

8

98.00

1.51

12

102.08

2.65

*Mean % recovery of five determinations.

of the estimate, standard deviation about regression,
or standard deviation of residuals, Sy/x. The smaller the
standard error of the estimate, the closer the points are to
the straight line.
(II) Detection and Quantification Limits
The detection limits were 8.01 × 10 -7 and 1.19 × 10 -6
M (0.38 and 0.42 µg/mL) for NF and VN, respectively,
while the quantification limits were 2.67 × 10 -6 and 3.97
× 10 -6 M (1.26 and 1.40 µg/mL) for NF and VN, respectively. These values were calculated according to the
formulae provided by the USP(43).
(III) Precision and Accuracy

the most suitable time intervals for measurements. The
calibration graphs were linear over the concentration
ranges of 6.33 × 10 -6 - 3.17 × 10 -5 M (3-15 µg/mL) and
1.13 × 10 -5 - 3.95 × 10 -5 M (4-14 µg/mL) for NF and VN,
respectively.
III. Analytical Performance of the Proposed Method
(I) Concentration Ranges and Calibration Graphs
The analytical parameters, molar absorptivities,
linearity ranges and regression equations calculated from
calibration graphs along with the standard deviations of
the slope (Sb), intercept (Sa) and the standard deviation of
residuals (Sy/x) are presented in Table 1. The values of the
correlation coefficients (r) of regression equations indicated good linearity and conformity to Beer’s law. The
linearity was also evaluated by calculation of percentage
relative standard deviation of the slope (Sb %). It was
found to be less than 2% for the developed analytical
method. An important statistic indicating the random
error in the estimated values of y is the standard error

Five replicate determinations at different concentration levels were carried out to test the precision and
accuracy of the proposed fixed time kinetic method. As
shown in Table 4, the % recovery and RSD (%) values
demonstrated the good repeatability and accuracy of the
proposed method.
(IV) Robustness
The robustness of the method was demonstrated by
the flexibility of the experimental factors that affect the
absorbance values. Variation of the volumes added of the
both NaOH and KMnO 4 solutions by ± 5% and variation
of the measurement wavelength by ± 2 nm did not have
significant effect on the measured absorbance values.
IV. Assay of Pharmaceutical Preparations
The fixed-time method was applied to the determination of NF and VN in their commercially available dosage forms. The fixed-time method gave better
linearity as indicated from the (r) values. In addition it
was easier in application than the rate constant method.
Direct application of the method on the aqueous extract
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Table 5. Application of the proposed kinetic method for the determination of NF and VN in their pharmaceutical preparations
Praxilene® tablets

Kinetic method

Reference methodb

%Recovery ± SDa

100.18 ± 1.84

99.87 ± 1.99

1.84

1.99

RSD %

b

t

0.26

F

1.17

Oxybral® capsules

Kinetic method

Reference methodc

%Recovery ± SDa

98.83 ± 0.74

99.52 ± 1.25

0.75

1.26

RSD %b
t

1.04

F

2.88

Oxybral® ampoules

Kinetic method

Reference methodc

%Recovery ± SDa

99.32 ± 1.13

100.04 ± 0.64

1.14

0.64

RSD %

b

t

1.25

F

3.12

a

Mean % recovery ± SD for five determinations.
b
Measurement of A max in saline at 283 nm(15).
c
Measurement of the first derivative of the ratio spectra (1DD293) of VN over 20 µg ml-1 standard VA(28).
Theoretical values for t and F at P = 0.05 are 2.31 and 6.39, respectively.

of Praxilene ® tablets resulted in a positive error in
recovery. This error can be attributed to the oxidation
of the common excipients usually present in the tablet
dosage form (e.g. lactose, starch, etc), therefore, acetonitrile was chosen as a dissolution medium and the reaction was applied on the acetonitrile aliquots. On the
other hand, because VN has a limited solubility in water,
acetonitrile was also chosen as a solvent for VN. For
Oxybral® ampoules, an extraction procedure with chloroform has been followed in order to eliminate the interference caused by the antioxidant present in the ampoules
which is easily oxidized by KMnO 4 yielding a positive
error in recovery values. The results obtained show good
precision and accuracy (Table 5) and they were statistically compared with those obtained by the reference
methods (15,28). The student’s t-test and the variance-ratio
F-test values at 95 % confidence level did not exceed the
theoretical values, indicating no significant difference
between the proposed and the reference method (Table 5).

Table 6. Effect of various foreign species on the determination of
NF and VN at the optimum conditions
Tolerance Limit (µg/mL)
Species

NF
(10 µg/mL)

VN
(10 µg/mL)

Glucose

12.35

12.77

Lactose

14.02

12.35

Sucrose

20.98

29.76

Starch

13.10

16.22

Ascorbic acid

23.44

25.42

Riboflavin

21.43

32.70

Carboxymethylcellulose

16.67

17.24

Hydroxypropylmethylcellulose

12.35

11.49

–––

5.45

Piracetam

V. Interferences
Interferences due to common excipients and related
co-formulated compounds were studied using glucose,
lactose, sucrose, starch, ascorbic acid, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, riboflavin and piracetam. Different aliquots of the interfering substance solutions in acetonitrile were added to

standard NF and VN solutions, treated and measured at
the optimum conditions for each compound. The tolerance limit (37) for each of these substances (Concentration
of interfering substance causing 3% relative error) was
calculated and listed in Table 6.
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CONCLUSIONS
In this study, a simple and sensitive kinetic fixedtime spectrophotometric procedure was developed
for the analysis of the two vasodilators: NF and VN.
Reviewing the literature exposed that there were no
reports for the kinetic spectrophotometic determination of the two drugs. Moreover, nothing was reported
concerning the use of colorimetry in the assay of NF,
and only single previous report for the UV spectrophotometric estimation of NF(15). On the other hand, very few
previous studies were concerned with the spectrophotometric or colorimetric analysis of VN. The simplicity,
convenience at low cost and sensitivity of the proposed
method are superior or comparable to those of the official
non-aqueous titration method (2) and several previously
published spectrophotometric methods (15,25-28,31,32).
Furthermore, the proposed method does not require
elaborate treatment or sophisticated experimental setup
usually associated with HPLC methods of analysis. The
developed method used only a spectrophotometer, which
is available in all quality control laboratories, and it
involved very simple procedure with readily available
chemicals (KMnO 4 and NaOH). The applicability of the
developed method was evaluated through the determination of the two drugs in bulk form and in pharmaceutical
formulations with good accuracy and precision, therefore
it can be considered useful and convenient for the routine
and quality control assay of the two drugs.
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